Menu Search Site

Bioinspired Approach to Sepsis Therapy

Previous Next

Wyss Institute Founding Director Don Ingber, Senior Staff Scientist Michael Super and Technology Development Fellow Joo Kang explain how they engineered the Mannose-binding lectin (MBL) protein to bind to a wide range of sepsis-causing pathogens and then safely remove the pathogens from the bloodstream using a novel microfluidic spleen-like device.

Credit: Wyss Institute at Harvard University

Close search results
Close menu